Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Tibet Pharmaceuticals Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Tibet Pharmaceuticals, Inc. (“Tibet Pharmaceuticals” or the “Company”) (OTC: TBET).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that Tibet Pharmaceuticals misrepresented and failed to disclose material internal control deficiencies, which rendered the Company's registration statement and prospectus to be materially false and misleading. These problems ultimately caused NASDAQ to halt and delist the Company’s stock.
If you purchased Tibet Pharmaceutical securities after December 28, 2010 and would like to discuss your legal rights, contact us by calling Juan Monteverde, Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com, firstname.lastname@example.org or email@example.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Tibet Pharmaceutical’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.